OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Paul E. Kalb, MD, is a former global practice leader, healthcare and FDA Group, for Sidley Austin LLP
The Caremark and Park doctrines require directors and managers of life sciences companies to address regulatory compliance proactively and vigorously.
Pharma companies should review their commission-based compensation arrangements with independent contractors to address enforcement risk under the Anti-Kickback Statute, in light of recent Department of Justice enforcement.
Companies that fail to comply with regulatory guidelines make easy targets for investigators.